File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials

TitleAssessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials
Authors
Issue Date2022
Citation
Expert Opinion on Emerging Drugs, 2022, v. 27, p. 127-140 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/318233
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHui, WHR-
dc.contributor.authorMak, LY-
dc.contributor.authorSeto, WKW-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2022-10-07T10:35:05Z-
dc.date.available2022-10-07T10:35:05Z-
dc.date.issued2022-
dc.identifier.citationExpert Opinion on Emerging Drugs, 2022, v. 27, p. 127-140-
dc.identifier.urihttp://hdl.handle.net/10722/318233-
dc.languageeng-
dc.relation.ispartofExpert Opinion on Emerging Drugs-
dc.titleAssessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials-
dc.typeArticle-
dc.identifier.emailHui, WHR: huirex@connect.hku.hk-
dc.identifier.emailMak, LY: lungyi@hku.hk-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityMak, LY=rp02668-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.doi10.1080/14728214.2022.2074977-
dc.identifier.hkuros336939-
dc.identifier.volume27-
dc.identifier.spage127-
dc.identifier.epage140-
dc.identifier.isiWOS:000796392900001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats